AZD4573
AstraZeneca selective CDK9 kinase inhibitor
"compound 42"
Bristol Myers Squibb (BMS) selective TNFα allosteric inhibitor
"compound 12"
AbbVie selective TNFα allosteric inhibitor
BMS-986202
Bristol Myers Squibb (BMS) oral JH2-domain binding Tyk2 kinase inhibitor
pamiparib
Beigene oral, brain-penetrant PARP1/2 inhibitor/DNA trapping agent
Linrodostat: An Oral Selective IDO1 Dioxygenase Inhibitor
Bristol Myers Squibb (BMS) oral selective heme-displacing IDO1 inhibitor
SAR439859: An Oral Selective Estrogen Receptor Degrader
Sanofi oral selective estrogen receptor (ER) degrader (SERD)
ACT-1004-1239: A CXCR7 GPCR Insurmountable Antagonist
Idorsia/Actelion CXCR7 GPCR insurmountable antagonist
Compound 1: An Anion-Dependent Farnesyl Transferase Inhibitor
Merck anion-dependent farnesyl transferase inhibitor
EB-42486
EB-42486 (ESCAPE Bio oral G2019S-LRRK2 mutant-selective kinase inhibitor)
"compound 4d"
“compound 4d” (Merck oral selective PI3K delta kinase inhibitor)
"compound 60b"
“compound 60b” (Taisho D486N mutant RSV fusion protein inhibitor clinical candidate)
"compound 15a"
“compound 15a” (Novartis reversible in vivo ATX inhibitor)
"compound 31"
“compound 31” (Merck cholesteryl ester transfer protein (CETP) inhibitor)
"compound 36"
“compound 36” (GlaxoSmithKline (GSK) oral TRPV4 ion channel antagonist backup)
BCPyr
BCPyr (Pfizer cIAP1-based BTK degrader)
"compound 4j"
“compound 4j” (Janssen (JNJ) brain-penetrant in vivo 5-HT2 antagonist and 5-HT7 inverse agonist, backup candidate)
LY3502970
Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist